These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 28010883)

  • 1. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study.
    Aaltonen K; Heinonen A; Joensuu J; Parmanne P; Karjalainen A; Varjolahti-Lehtinen T; Uutela T; Puurtinen-Vilkki M; Arstila L; Blom M; Sokka T; Nordström D
    Semin Arthritis Rheum; 2017 Jun; 46(6):732-739. PubMed ID: 28010883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland.
    Aaltonen KJ; Joensuu JT; Pirilä L; Kauppi M; Uutela T; Varjolahti-Lehtinen T; Yli-Kerttula T; Isomäki P; Nordström D; Sokka T
    Scand J Rheumatol; 2017 Sep; 46(5):359-363. PubMed ID: 27931158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France.
    Soubrier M; Pereira B; Frayssac T; Abdi D; Couderc M; Daron C; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Clin Exp Rheumatol; 2016; 34(6):1059-1064. PubMed ID: 27607233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
    Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
    Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis.
    Tillett W; Shaddick G; Jobling A; Askari A; Cooper A; Creamer P; Clunie G; Helliwell PS; James J; Kay L; Korendowych E; Lane S; Packham J; Shaban R; Thomas ML; Williamson L; McHugh N
    Rheumatology (Oxford); 2017 Apr; 56(4):603-612. PubMed ID: 28013211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings.
    Iannone F; Lopriore S; Bucci R; Lopalco G; Chialà A; Cantarini L; Lapadula G
    J Rheumatol; 2016 May; 43(5):911-7. PubMed ID: 26980583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study.
    Heinonen AV; Aaltonen KJ; Joensuu JT; Lähteenmäki JP; Pertovaara MI; Romu MK; Hirvonen HE; Similä AK; Blom ML; Nordström DC
    J Rheumatol; 2015 Dec; 42(12):2339-46. PubMed ID: 26472421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.
    Ungprasert P; Thongprayoon C; Davis JM
    Clin Rheumatol; 2016 Jul; 35(7):1795-803. PubMed ID: 26852316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM; Marchesoni A; Lubrano E
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.
    Saad AA; Ashcroft DM; Watson KD; Hyrich KL; Noyce PR; Symmons DP;
    Arthritis Res Ther; 2009; 11(2):R52. PubMed ID: 19356232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.
    Stober C; Ye W; Guruparan T; Htut E; Clunie G; Jadon D
    Rheumatology (Oxford); 2018 Jan; 57(1):158-163. PubMed ID: 29077973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.
    Kristensen LE; Lie E; Jacobsson LT; Christensen R; Mease PJ; Bliddal H; Geborek P
    J Rheumatol; 2016 Jan; 43(1):81-7. PubMed ID: 26628604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry.
    Højgaard P; Glintborg B; Hetland ML; Hansen TH; Lage-Hansen PR; Petersen MH; Holland-Fischer M; Nilsson C; Loft AG; Andersen BN; Adelsten T; Jensen J; Omerovic E; Christensen R; Tarp U; Østgård R; Dreyer L
    Ann Rheum Dis; 2015 Dec; 74(12):2130-6. PubMed ID: 25063827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment persistence of biologics among patients with psoriatic arthritis.
    Haddad A; Gazitt T; Feldhamer I; Feld J; Cohen AD; Lavi I; Tatour F; Bergman I; Zisman D
    Arthritis Res Ther; 2021 Jan; 23(1):44. PubMed ID: 33514410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.